Emily Hill - Director, Investor Relations Stuart Peltz - Chief Executive Officer Shane Kovacs - Chief Financial Officer Mark Rothera - Chief Commercial Officer.

Jason Kantor - Credit Suisse Alethia Young - Deutsche Bank Tazeen Ahmad - Bank of America Christopher Marai - Oppenheimer Debjit Chattopadhyay - ROTH Capital Partners Ritu Baral - Cowen and Company.

Thank you for holding for PTC’s Third Quarter 2014 Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, PTC management will open the lines for a question-and-answer session.

Please be advised that the call is being taped at the Company’s request and will be archived on the company’s website until December 5th. PTC’s current investor presentation slide deck is available at the same website location. At this time, I’d like to turn the call over to Emily Hill of PTC..

Thank you, operator, and good afternoon, everyone. Thank you all for joining us for PTC’s third quarter 2014 financial results conference call. With me here today are Dr. Stuart Peltz, Chief Executive Officer; Mr. Shane Kovacs, Chief Financial Officer and Mr. Mark Rothera, Chief Commercial Officer.

Stuart will provide opening remarks and share some highlights of the quarter and recent events. Shane will then provide detailed financial results, and we will open up the call for questions. Earlier this morning, we issued a press release detailing PTC’s third quarter 2014 financial results, which is available on our website at ptcbio.com.

During today’s call we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

These include statements about our future expectations, regarding clinical developments, regulatory, and commercialization timelines, the potential success of Translarna and other product candidates and financial projections.

Actual results may differ materially from those indicated by these statements as a result of a variety of risks and uncertainties including those discussed under the heading special notes regarding forward-looking statements and risk factors in our most recent form 10-Q and our prospective supplement filed on October 10, each of which are on file with the SEC.

Any forward-looking statements represent our views as of today only. PTC undertakes no obligation to publicly update any forward-looking statements. With that, let me pass the call over to Stuart..

Thanks Emily, and good morning, everyone. Welcome to our third quarter 2014 investor conference call. It’s busy and exciting time here at PTC with multiple programs moving forward. A number of important activities are occurring with our lead product Translarna.

We are well advanced in our prelaunch activities of Translarna for Duchenne muscular dystrophy in Europe and other parts of the world. We also expect to submit a new drug application to the FDA on a rolling basis for Translarna for DMD in the US by the end of 2014.

In addition to our work in DMD, we are currently enrolling the second Phase 3 trial ACT CF with Translarna for patients with nonsense mutation cystic fibrosis. As you’ve heard me say before, Translarna is both the product and a pipeline and we’re actively pursuing additional indication. I’ll tell you a bit more about these later.

We are also very committed to utilizing our platform technologies to discover and develop additional therapies for ultra-orphan disorders. For example, our spinal muscular atrophy program also is advancing into a Phase 2 clinical trial called MOONFISH later this month. This program is partnered with Roche and the SMA Foundation.

Let me take you through some of these milestones in detail. As you may recall, Translarna is now approved in the EU for the treatment of the Duchenne muscular dystrophy caused by a nonsense mutation in the ambulatory patients age five years and older. Translarna is the first ever treatment to be approved for the underlying cause of DMD.

This approval allows us to provide Translarna to patients in 28 countries in the EU as well as in other countries outside the EU that recognize this. Our commercial activities and preparation for the launch of Translarna are well underway.

We are highly engaged with regulators, payers, physicians and patient organizations to bring Translarna to patients as quickly as possible. We’ve assembled a leading team of professionals with rare and orphan disease launch experience in key countries including Germany, UK, Italy, France, Spain and the Nordic region.

Our commercial organization also includes strong global and regional support capabilities all the way through supply chain and distribution. We are very aware that every day counts for patients and their families living with DMD, an irreversible muscle wasting disorder.

Where mechanisms exist, we are making Translarna available to DMD patients through reimbursed early access program. For example, funded main patient programs have been authorized in Israel, Turkey and Spain. In France, we were granted an ATU cohort by the French Medicine Agency.

Throughout the third quarter, the EAP programs have gaining momentum and I’m happy to say that PTC been shipping Translarna to patients enrolled in these program and we have already booked up for sale this quarter.

Most recently, Translarna have been authorized for inclusion into Italian Law 648 program which allows reimbursed early access for cohort to patients in Italy. We continue to work to expand our early access program. Meanwhile, we are moving forward with the commercial launch of Translarna.

We expect the first commercial sale to be in Germany in the next few months. In addition to these activities in Europe, we are also working to bring Translarna to patients in other regions starting with Canada and Latin America. These are regions that can recognize the European decision as part of granting reimbursed early access to patients.

As a reminder, we have world-wide commercial rights to Translarna and it’s our goal to bring this DMD treatment to patients globally. We have started the market access dossiers in Europe and anticipate country by country negotiations to establish a commercial price of Translarna throughout 2015 and beyond.

Innovative ultra-orphan drugs of this category are usually priced in a range of $200,000 to $400,000 per patient per year. Our current internal base case assumption is that Translarna will be priced at about $300,000 per year for a typical patient. In September our Phase 3 ACT DMD trial completed an enrollment.

Top-line data from this trail is expected in the fourth quarter of 2015. As patients complete this trail, they’ve been rolling on to an open label extension study. With over 220 patients enrolled, we believe this is the largest study ever to be conducted in DMD.

Regarding regulatory approval of Translarna for DMD patients in the US, we’ve been in dialog with the FDA. We now intend to initiate a rolling NDA permission by the end of this year for the approval of Translarna for DMD in the US.

This process gives the FDA an opportunity to conduct meaningful review of most the segments of our NDA ahead of reviewing our Phase 3 ACT DMD data. We expect that the submission of this confirmatory Phase 3 data will complete our rolling NDA.

Based on our discussions with the FDA, we expect that our rolling NDA will be rapidly reviewed for potential to approval within the first half of 2016. Translarna is not just for DMD. We are also highly focused on the development of Translarna as a treatment for cystic fibrosis.

Nonsense mutations are present in approximately 10% of all CF patients and because of the complete lack of reduction of the CFTR protein, nonsense mutation CF is one of the most severe forms of the disease. Available treatments today do not address the underlying cause.

We are currently enrolling our confirmatory Phase 3 clinical trail ACT CF in nonsense mutation CF patients. We anticipate that we will complete enrollment of approximately 200 patients in the second half of 2015 with data expected approximately a year later.

We intend to submit an MAA for conditional approval for Translarna in CF in Europe in mid 2015 with the clinical results achieved from our prior Phase 3 trial. Based on our experience with the EMA for DMD approval, we believe it is important to the CHMT that our confirmatory Phase 3 ACT CF trail be well underway prior to seeking an approval.

In addition to DMD and CF, we are also actively planning for the development of Translarna for other nonsense mutation patient disorder. In the past several years, there been over 20 publications by independent investigators demonstrating Translarna’s activity in multiple disease models.

We have decided to start with MPS I as a next indication for Translarna. Our goal is to initiate a Phase 2 proof of concept study by the end of this year. We are also actively evaluating additional indications to pursue in order to realize Translarna’s full potential.

Let’s now turn to our alternative splicing platform where the lead program is focused on spinal muscular atrophy or SMA. To remind you, this is another program that was discovered in-house by PTC’s research team. This program is in collaboration with both Roche and the SMA Foundation.

SMA is a rare disorder that is the leading genetic cause of death in infants and in toddlers. The SMA Foundation estimates that spinal muscular atrophy affects one in every 10,000 children born. It is caused by a defective SMN1 gene leaving SMN protein production solely as a result of the expression of the SMN2 gene.

This leads to reduced levels of the SMN proteins causing motor neuron death a significant muscle atrophy and eventually death by the age of two in the most severe form of the disease. As we previously disclosed a Phase 1 trial was completed earlier this year. This was a single ascending dose, placebo-controlled study in healthy volunteers.

The primary objective of this study was to explore safety and pharmacokinetics of the oral drug candidate RG7800. Preliminary findings in the study demonstrated that RG7800 was well-tolerated at all dose level study. There were no serious adverse event and no dose related AE trends were identified.

It is worth noting that RG7800 demonstrated a dose-dependent effect on SMN2 splicing is measured in blood which we interpret as proof of mechanism. A Phase 2 trial known as MOONFISH in SMA patients is expected to begin later this month. We expect this will trigger a milestone payment from Roche to PTC.

This will be a multi-center randomized, double-blind placebo controlled multi-dose study. Once-daily oral dosing over a 12-week period will take place in patients 2 to 55 years of age. Safety and tolerability are the primary outcome measures.

Important secondary outcome measures include pharmacokinetics parameter and SMN mRNA level and SMN protein production as measured in the blood. Electrophysiology will also be evaluated as potential efficacy outcome measures.

We believe that the results we have achieved to date in this program provides strong validation for our alternative splicing platform. We are focused on leveraging our splicing platform to discover new compound to include or exclude exons in RNA transcripts to treat other rare and neglected disorder.

We look forward to discussing our pipeline in greater depth including our early cancer stem cell and antibacterial program at our Science Day on November 24th in New York City. Before we open the call for Q&A, let me ask Shane to review our financial results.

Shane?.

Thanks, Stu. I am happy to again report that PTC is in a very strong financial position which will support our important ongoing commercial, regulatory, clinical and research activities. We finished the quarter ending September 30 with nearly $210 million of cash and marketable securities on our balance sheet.

In October, we completed a very successful financing through a public offering of common stock where we secured an additional $117.5 million of net cash proceeds. Pro forma for this offering, we had approximately $327 million of cash on our balance sheet at September 30th.

We believe that this cash position should be sufficient to fund our operation for the next three years through late 2017. Here are the financial highlights from our quarter and our updated financial guidance.

As Stu mentioned earlier, we achieved an important milestone in the third quarter recognizing the first product sales for Translarna in history of PTC via our European reimbursed early access programs. It is important to note that we are booking revenue on a cash basis when payment is received as oppose to when product is shipped.

Therefore, in the quarter, we had shipped more products that we are able to recognize as revenue. Total revenues for the third quarter of 2014 were approximately $1.7 million compared to total revenue in the third quarter of 2013 to $16.3 million. This includes revenue of approximately $0.1 million from net product sales of Translarna.

Revenue from grants and collaborations was $1.6 million for the third quarter of 2014 compared with $16.3 million for the same period in 2013.

This decrease was due to a milestone payment of $10 million that was recognized in the third quarter of 2013 related to the SMA collaboration as well as a decrease in the recognition of non-cash deferred revenue.

R&D expenses were $18.8 million for the third quarter of 2014 including $2.4 million in non-cash stock-based compensation expense compared with $13.9 million for the same period in 2013 which included $0.7 million in non-cash stock-based compensation expense.

The increase was primarily a result from additional costs associated with clinical trials and stock-based compensation.

General and administrative expenses were $10.5 million for the third quarter of 2014 including $2.3 million in non-cash stock-based compensation expense compared with $6.7 million for the same period in 2013 which included $2 million in non-cash stock-based compensation expense.

The increase primarily results from additional costs associated with commercial activities in support of the launch of Translarna across Europe and legal costs associated with establishing our international infrastructure.

The company reported a net loss of $27.3 million for the third quarter of 2014 compared with approximately $4.4 million for the third quarter of 2013. We recently established our International Headquarters in Dublin Ireland.

This office was served as the central hub for the commercial launch of Translarna on a global basis and will enable PTC to take advantage of its proximity towards third-party manufacturing and supply chain.

Over the longer term, we believe this corporate structure could result in a blended tax rate in the low teens based on global sales of Translarna.

Based on our current run rate of expenses, we now expect total cash operating expenses to be between $93 million and $103 million excluding expected non-cash stock-based compensation expense of approximately $17 million for total operating expenses of approximately $110 million to $120 million.

As a result of our recent financing we now expect to end 2014 with approximately $295 million to $305 million in cash, cash equivalents and marketable securities. This does not include the anticipated $10 million milestone payment from Roche that we expect to receive upon the initiation of the MOONFISH study.

We currently have 33.6 million shares issued and outstanding which includes $0.7 million shares in restricted stock grants. Joining us for our Q&A is our Chief Commercial Officer Mark Rothera.

Operator, can we now take the first question?.

(Operator Instructions) And our first question comes from Jason Kantor of Credit Suisse. Please go ahead..

Perfect.

Can you hear me?.

Yes..

Any chance you guys could give us the patient number in terms of how many patients are on these named-patient programs in Europe at the moment?.

Yes, hi Jason. Good to hear from you. So, these are just continual process, I don’t think we’re putting out numbers right now. Obviously in terms of the number of patients, we’re just not saying, obviously we’re working on those who are genotype and it will be variable from country to country. So, at this time we’re not just putting out that..

And could you give us some expectation maybe quarter-by-quarter, how would you see the actual commercial launch rolling out in 2015? I think that would help..

Yes, hi. Let me ask Mark to talk a bit about that..

Yes, hello. So, we’re really planning for our first commercial launch in Germany in the next few months. And if you look typically countries in the Nordic region are typically some of the fastest commercial reimbursement processes out there.

So, coupled with UK, we see sort of Germany, the Nordic region, UK has being in that sort of first wave of launches in the first half 2015..

And do you expect to be launched throughout Europe by the end of 2015, is that -- should we assume that?.

I think we said this before but the pricing reimbursement processes in Europe can take anywhere from around three months to 18 months plus.

So, there maybe a few countries in 2016 that will reimburse but I guess the good news is we have made good progress with the early access program in countries like France and recently we are now in Italy, but thanks to the fact that these authorities have reimbursed early access program, it’s essentially like a launch and you are sort of bringing, and there you can’t in these circumstances promote, but you can provide the drug on a reimbursed basis to patients when physicians request it..

Got it. Thank you..

Our next question comes from Alethia Young from Deutsche Bank. Please go ahead..

Hi, great. Thanks for taking my question and also let me be the first to congratulate you on your first sales in the Company’s history. I have a couple questions.

One, just kind of following up on Jason’s question, can you talk a little bit about perhaps maybe more of it, some flavor for the numbers in some of these early markets or kind of how you think about like the population size there? And then I guess the next question is, kind of how do you think about variance on pricing as far as like is $300 a reasonable average price or how should we think about it country to country and how did this conversation go the kind of established in this whole kind of average price that you are comfortable communicating? Thanks..

Hi, Alethia, thanks. So, now that we have the first available treatment for the underlying cause of DMD. There is a real, much greater incentive to genotype of patients, right. So, that’s going on right now. So, let me pass it on maybe to Mark to actually give you the color on what’s you’re….

If I understood, you’re sort of talking about patient numbers and the pricing. So, I think we said this before but we’re expecting that within the label in Europe. We’re talking around 40% to 50% of nonsense mutation for Duchenne muscular dystrophy patients falling in the label.

And as to pricing, I think you’re very well aware that innovative ultra-orphan drugs in this sort of category are usually priced in the range of $200,000 to $400,000. We made it clear that our internal assumption is around $300,000 plus or minus.

And because there are so many variables to the price including weight of the patient, the exchange rate and the country specific mechanisms of reimbursement, already directing you to the best estimate of the overall anticipated price for patients for a year from a planning perspective..

Great. Thanks..

Our next question comes from Tazeen Ahmad from Bank of America. Please go ahead..

Hi, thanks for taking my questions. A couple on the SMA trial, so for MOONFISH, you noted that you’re starting with patients that at age two.

Can you just kind of tell us sort of the rationalization behind that? Why not start with younger patients? And given the fact that you’re starting the trial imminently, is it possible that we could expect data from that before the end of 2015? And the third question is on the first trial in healthy patients, when do you think we could potentially see additional data from that potentially at a medical meeting?.

Yes, hi. Thank you for your question. And just to remind you that the 2 to 15 really is really going to be Type 2 and 3 patients initially. So, that’s what we’ll comment. Obviously, we’ll be -- we’re looking at to start a trial also at some point in the Type 1 patients but that will -- that’s not what predominantly this trial will be about.

So that was the reason why that would be. In terms of when we anticipate data, obviously this is – we’re starting this month. And so I think if you look in the ClinicalTrials.gov we say we anticipated the completion as of January 2016 that can be faster depending on the enrollment.

So, we certainly anticipate within that year and it could even be more rapid than that..

And then on the healthy patient data, have you discussed with Roche an appropriate venue for that?.

Yes. So, obviously we did the healthy volunteer data where we showed the proof of mechanism and everyone was pretty excited about that. We want to share this data and we’re looking at what the best scientific venue is to present that in 2015..

Okay. And I guess one question for Shane, I think in your 2Q filing, you did disclose that you establish a new subsidiary, is that being -- is that being looked after potentially helping you lower your US tax rate, and if so, when do you think you would get some - we would get some clarity on that? Thanks..

Yes, well I think we just kind of earlier said in the script about the proximity of our supply chain and our distribution for Ireland being sort of the central hub. And then ultimately I think we said that we anticipate the discorporate structure could result in a blended tax rate in to low teens based on global sales of Translarna..

Would that be something that you would have a better sense on the closer you get to commercialization?.

Yes, I mean obviously we still have a lot of tax losses and so when we ultimately be cash flow positive in the coming taxes is in future years, so it is some ways away but I think based on the structure that we have in place and what some of our peers have come to, I think that’s our current expectations..

Okay. Thanks..

Our next question comes from Chris Marai of Oppenheimer. Please go ahead..

Hi. Thanks for taking my questions and congratulations on your first sales. I guess, first, sort of wondering about your extended access demand here.

Are these patients had -- are they patients that have previously been enrolled in trials, enrolled orphan ultra drugs or are they’re new patients? And then, could you comment potentially on patients that have been genotypically confirmed already, how many have been confirmed by your estimates in the marketplaces? Thanks..

Yes, sure. So, these are patients, so obviously when we were doing the confirmatory I mean the confirmatory actually DMD trial that these patients we wanted those patients in the trial. So, these are all new patients who either don’t fit well within the current trial but within the label. So, that’s this new patient population that are in.

In terms of the genotyping, obviously we think that’s an critical part of what we’re going to do because obviously now there is a treatment, approved treatment for patients now with for DMD but that have the particular genotype and that we think as important in order to – obviously to know what the patient population is and we’re making every effort to really make sure that all known patients are genotype and that’s really one of the top things in our list to work on.

And Mark, maybe you want to make any comments?.

Yes, I just wanted to echo your words, Stu, that there is variability between countries as a number of patients that are known in genotype. And it is one of our really big areas of focus of putting in place different processes and supporting mechanism and sort of – and that awareness and enable faster and more efficient genotyping of patients.

And as you said, I think it’s a very critical to identifying the right patient and Translarna is really a key to the success with Translarna and PTC..

Okay, great.

And then just with respect to that question on the patients, have they been previously exposed to Translarna? Could you comment on that, the patients who are now on therapy through your expanded access program?.

These are all new patients. Patients that have been previously been exposed are on our extension clinical trial program so right now that’s where they’re at. So, these are all brand new patients..

Okay, thanks. That’s helpful. And then just with respect to ex-EU expanded access demand, are you seeing demand from patients outside the EU and have any patient in Brazil started the process to or request the right to the drug? Thanks..

So we’re working now in other countries as well outside the Europe including Israel, Colombia as well as in Brazil to try and get expanded access. What we’re trying to do is obviously use the approval process in those countries that will allow you to use expanded access based on the approval in Europe. And so we’re working there as well.

Actually we’re also in Canada and other places as well in terms of that for the approval of potential expanded access. So, we’re working on that right now..

Great. And then one last question, just about the rolling NDA in the US, congratulations. I’m just wondering with respect to that, is this going to significantly impact your previously guided timelines with respect to a potential Translarna US launch. Thanks..

Thanks.

I think that, the way we’re thinking about this is that as I said discussions with the FDA, that will get the various segments of the NDA in and then on completion of the ACT DMD trail the data will come out and we’ll then expeditiously get it in and it’s our hope and I think and our dialog with them given the severe unmet medical need that this would be rapidly reviewed and that, that this was expected in terms of the approval to move it up potentially up to six months.

So, I think what we’re thinking about that is that we would think that this can be a launch within the first half of 2016..

Great. Thanks for taking my question. Congratulations on the FL..

Thank you..

Thanks Chris..

(Operator Instructions) And our next question comes from Debjit Chattopadhyay from ROTH Capital Partners. Please go ahead..

Hey, good morning, guys. And thanks for taking my question.

Considering that SMA Type 1 is probably a more – in more a need for disease modifying therapy compared to DMD, what are you thinking about in terms of solid endpoint, given that you have a biomarker to maybe have an isolated approval process for the SMA Type 1 indication as opposed to going for hard endpoint like time to death or post-activation?.

So, in Type 1, I mean in Type 2 what we’re doing right now is really in patient what we’re looking at is the SMN both RNA and protein levels as well as some function that’s measured by physiology. So, I think those would be the first part which certainly we’re looking at is the potential for as a biomarker as well.

And so those are going to be future discussions with the FDA and the European regulators as their thoughts on biomarkers but certainly we’re gathering that sort of information to be able to have those discussions at a future time..

And the other pertains to the commercial launch in Europe, are you guys are considering some sort of centralized lab to expedite the genotyping of patients, so that you get as many as possible within the next year or so, Stu, on the drug?.

Yes, I think what we’re to say that we’re trying whatever avenue is possible to make sure that we get genotype set the rate limiting step is not actually getting the information for genotyping. And so I think really our goal is to identify and do this rapidly as possible..

And maybe I can add that given the fact that you’re dealing with the multiple set of countries with different languages and different systems, our general preference has been to find a key laboratory in each country, some of them are already exist and funneling patients into that diagnostics has played very well, some of them are not quite so well organized and our job is to enhance awareness.

And in fact patients are much more aware now of the need for genotype than they were in the past because there is now a treatment so it increased the demands for genotype..

And one last question, since that Translarna is on a conditional approval, have you had any push back from any reimbursement authority regarding your reimbursement rates until your Phase 3 data is out there?.

Yes, so the conditional approval really just the point that others really an approval with the requirement to do another study analogous to probably like an accelerated approval in that point of view. I think in terms of push back, in terms of this, it’s probably too early to make any comments on the negotiations at this time..

We’re expecting our negotiations throughout 2015..

So, thank you so much and congratulations once again..

Thank you..

Our next question comes from Ritu Baral from Cowen. Please go ahead..

Hi, guys. I appreciate you taking the question.

In regards to the $300,000 price that you mentioned, is that typically a potential pan-European planning price or does that extend to your worldwide internal estimates as well?.

Yes. So, we’re – we don’t yet have the final commercial price and that’s going to be something that you negotiate country by country. So, I think we’re in the process of submitting all the reimbursement dossiers in the multiple countries and we anticipate price negotiations to occur throughout 2015 and perhaps even beyond.

So, it’s hard to actually give you anything more precise than that..

Okay.

And then as we look at Canada and Latin America as you mentioned, what sort of general patient numbers exist there? Is the prevalence of nonsense are more to the US and Europe? And also what sort of timeline following the EU reimbursement or approval to those regions generally follow with orphan drugs in particular?.

Yes, so maybe I’ll just say the normal prevalence that I think that we’ll look at is what we’ve been saying is approximately 13% of the patients. And in the case of Duchenne muscular dystrophy, there is not a particular ponderous effect. In fact about 40% or so are spontaneous type mutation.

So, you really see this worldwide and that number is somewhat typical. And so obviously which is a really some high amount of medical need. And so we’re trying to expedite those processes maybe Mark, have you -- give a little bit of the timelines in those countries..

I would just say that like some of those countries we’ve seen in Europe, countries like Brazil and Canada do have early access mechanisms on a named-patient basis. And I think our initial expectation is that the demand that we’re already feeling from those countries will be better to the named-patient processes..

Do you think that could be a 2015 something that we should consider for our models for 2015 or would that be more of a 2016 thing?.

It could be possibly towards the back-end of 2015 and into 2016, it’s generally a kind of inertia in getting these systems up and running..

Perhaps on the – in terms of thinking like the launch in the US when you compare that where we think in the first half of 2016 the US launch is what we’re anticipating. It could be in terms of approvals, approval so it could be similar to that nature, right..

Great, that’s really helpful. And my last question, going back to the genotyping rates, you’ve presented, I think some interesting market data on the overall rate, current level of genotyping in Europe which disagrees with some of the very anecdotal numbers that the European doctors believe their patients are genotyped.

What are your current thoughts, if not on the actual numbers patients genotyped, just the current percentage and how that might grow?.

Yes, I think in terms of the numbers, I don’t think we’ve actually gone through and discussed too many numbers. So, and actually we’re on that point.

Maybe Mark, do you want to have?.

Yes, I wonder whether you might be thinking about the fact we reported a 40% to 50% of nonsense mutation in patients from a prevalence point of view being within our label..

Go ahead, sorry..

Sorry, that’s just an -- I don’t think we’ve given you a specific number of known nonsense mutation patients statistics..

But do you have any sort of internal estimate on the degree that European patients are genotyped right now and how that might grow?.

So, it does vary by country, some are very sophisticated and very centralized, some are little less sophisticated. We don’t have one number to give you at this stage but I think as Stu mentioned earlier, we’re highly focused on helping different medical systems in different countries to be as efficient as possible about the whole diagnostic pathway.

We realize that’s really critical even if this is a very target we mentioned..

Great. Appreciate you guys taking the questions..

There are no further questions at this time. I would like to turn it back to Stuart Peltz, for closing remarks.

Thank you, operator. It’s been over 15 years of research and development to bring the first commercial therapy to Duchenne patient. We’re very engaged in this launch process and look forward to updating you further.

Also, please either join us in New York City or on the webcast for our Science Day on November 24th to hear more about our continuing progress and our developing pipelines. Again, thank you for your interest in PTC and for joining the call today..

Ladies and gentlemen that does conclude today’s conference. Thank you for your attendance. You may now disconnect. Everyone, have a great day..